BCD-245 is under clinical development by Biocad and currently in Phase I for Osteosarcoma. According to GlobalData, Phase I drugs for Osteosarcoma have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BCD-245’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BCD-245 overview
BCD-245 is under development for treatment of neuroblastoma, osteosarcoma, Ewing sarcoma, rhabdomyosarcoma and soft tissue sarcoma. It acts by targeting GD2 and is administered through intravenous route.
Biocad overview
Biocad is a biotechnology company that conducts research and development services. The company develops, manufactures, and distributes generic pharmaceutical products. Its products portfolio comprise rituximab, bevacizumab, trastuzumab, prolgolimab, levilimab, netakimab and eculizumab. Biocad develops products in the form of suppositories, spray, and drops. The compay provides products under the brands Avegra, Herticad, Gerticad, Forteka, Extimia and Leucostim. It manufactures products in the therapeutic areas such as oncology, orphan disease and autoimmune diseases. The company operates in Brazil, China, Russia, the UAE and Vietnam. Biocad is headquartered in Saint-Petersburg, Russia.
For a complete picture of BCD-245’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
